The Effect of Idoxuridine (IDU) on Corneal Stromal Cells in Tissue Culture

Corneal stromal cells were cultured in vitro and exposed to various concentrations of idoxuridine (IDU), ranging from 0 to 1,000 μg of IDU per ml of medium. Inhibition of cell multiplication occurred with concentrations of 0.1 μg per ml. With concentrations of 1.0 μg per ml and greater, there was no increase in cell number from the time of exposure to IDU

CD8(+), HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

A CD8(+ )cytotoxic T lymphocyte (CTL) line was derived from the peripheral blood mononuclear cells of a patient with primary melanoma. The CD8(+ )CTL line specifically lysed the autologous primary melanoma cells and not the natural killer cell-sensitive K562 cells or lymphokine activated killer cell-sensitive DAUDI cells. When a large panel of human leukocyte antigen (HLA)-matched and -unmatched allogeneic melanoma, glioma, breast and colorectal carcinoma cells was tested as targets in cytolysis assays, 4 HLA-matched and two HLA-unmatched allogeneic metastatic melanoma lines were lysed by the CD8(+ )CTL. Lysis of autologous and allogeneic melanoma cells was dependent on the effector-to-target cell ratio. Lysis of autologous melanoma cells was not blocked by anti-HLA class I or class II antibodies, confirming that the cytolytic activity of the CD8(+ )CTL was HLA-unrestricted. CTL lysis of autologous melanoma cells was CD3 (T cell receptor) dependent and FAS-FAS-L, and CD1 independent. Identification of the melanoma-associated antigen recognized by the HLA-unrestricted CTL may provide a vaccine for a broad population of melanoma patients

Traumatic Hyphema: A Review of Experience at the Medical College of Virginia During the Past Decade

Hyphema (hemorrhage into the anterior chamber of the eye), as the result of blunt injury to the eye, carries a potential danger of visual loss if not properly treated. This review of cases seen in the MCV Hospitals over the last decade lists some of the complications and stresses some of the important factors in the management

CD8⁺, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Abstract A CD8+ cytotoxic T lymphocyte (CTL) line was derived from the peripheral blood mononuclear cells of a patient with primary melanoma. The CD8+ CTL line specifically lysed the autologous primary melanoma cells and not the natural killer cell-sensitive K562 cells or lymphokine activated killer cell-sensitive DAUDI cells. When a large panel of human leukocyte antigen (HLA)-matched and -unmatched allogeneic melanoma, glioma, breast and colorectal carcinoma cells was tested as targets in cytolysis assays, 4 HLA-matched and two HLA-unmatched allogeneic metastatic melanoma lines were lysed by the CD8+ CTL. Lysis of autologous and allogeneic melanoma cells was dependent on the effector-to-target cell ratio. Lysis of autologous melanoma cells was not blocked by anti-HLA class I or class II antibodies, confirming that the cytolytic activity of the CD8+ CTL was HLA-unrestricted. CTL lysis of autologous melanoma cells was CD3 (T cell receptor) dependent and FAS-FAS-L, and CD1 independent. Identification of the melanoma-associated antigen recognized by the HLA-unrestricted CTL may provide a vaccine for a broad population of melanoma patients.</p